Short interest data and graph and individual analyst estimates and ratings
- Individual analyst names with their specific EPS, revenue, R&D, and SG&A estimates broken out in the consensus estimates panel 2.C onsensus estimates panel should include analyst averages for R&D and SG&A line items, not just EPS and revenue — especially critical for biopharma where R&D spend is a primary value driver
- Product/asset-level revenue breakdown panel — both reported actuals and analyst consensus estimates per drug — critical for biopharma where a single asset like Keytruda or Ozempic can drive the majority of company value
- Short interest panel showing short interest, days to cover, and short interest change over time for individual tickers
- SEC filings panel — dedicated panel surfacing 10-K, 10-Q, and 8-K filings for a focused ticker directly in the view
- 13F investor panel — track position changes from named specialist biopharma funds (RA Capital, Baker Brothers, ARK Invest, Perceptive Advisors, Orbimed) with their latest filings, new positions, additions, reductions, and exits, filtered by watchlist tickers
- Fund directory panel — curated list of specialist biopharma/healthcare investors with their latest 13F summary, AUM in biopharma, and top holdings, clickable to drill into their full position list
- Institutional investors/shareholders panel — live panel showing top holders, ownership percentage, and quarter-over-quarter changes for a focused ticker
- AlphaSpace could enable masses to invest better if it evolves toward a FactSet-level biopharma research experience — with analyst-level estimates, product revenue breakdowns, specialist fund tracking, and pipeline catalyst monitoring built into a single workflow
1st
ranked
Paurav Desai
shared this idea